Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia (HU)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Children's Mercy Hospital Kansas City
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Kathleen A Neville, Children's Mercy Hospital Kansas City
ClinicalTrials.gov Identifier:
NCT01506544
First received: September 30, 2011
Last updated: May 31, 2013
Last verified: May 2013
  Purpose

Hydroxyurea (HU) is approved by the United States Food and Drug Administration (FDA) to treat adults with sickle cell anemia. Hydroxyurea has also been tested and used with children with sickle cell anemia. However, there are not many studies describing the disposition of drug in children less than 5 years old. The FDA has requested this study to better understand how children ages 2 to 17 years with sickle anemia absorb and eliminate the drug (this is called pharmacokinetics). The investigators will measure how much Hydroxyurea (HU) gets into the bloodstream at different time points after taking this medication.


Condition Intervention Phase
Sickle Cell Anemia
Drug: Hydroxyurea
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia

Resource links provided by NLM:


Further study details as provided by Children's Mercy Hospital Kansas City:

Primary Outcome Measures:
  • Composite of Pharmacokinetics [ Time Frame: predose, 0.17, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    Cmax, Area Under Curve, Tmax. Also, the following pharmacokinetic parameters will be derived for each participant using standard techniques: Apparent absorption rate constant, Apparent terminal elimination rate constant, Apparent steady state volume of distribution, Apparent plasma clearance. A compartment, model-based, classical fitting paradigm of the plasma concentration vs. time data will be applied to each subjects' data. Standard goodness of fit criteria will be employed. Subjects aged greater than or equal to 2 and less than or equal to 17 years.

  • Pharmacokinetics of HU [ Time Frame: predose, 0.17, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    To evaluate the relative bioavailability of a liquid HU formulation (100mg/mL0 in participants ages greater that 5 and less than or equal to 17 years of age compared to standard therapy utilizing Droxia 200mg capsules


Secondary Outcome Measures:
  • Bioavailability of HU [ Time Frame: predose, 0.17, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8 hours post-dose ] [ Designated as safety issue: No ]
    Relative bioavailability of liquid HU formulation in comparison to Droxia® capsules will be assessed according to published FDA Bioequivalence Guidance Subjects aged greater than 5 and less than or equal to 17 years Derived steady-state PK parameters after multiple doses of liquid HU (AUC(0-12), AUC(0-∞), Cmax, Tmax, and t½) Steady-state plasma(PK)parameters for liquid formulation of HU will be evaluated Subjects ages greater than or equal to 2 and less than or equal to 5 years will receive doses of 20mg/kg/day for at least 4 consecutive days before evaluation of the steady-state parameters


Estimated Enrollment: 40
Study Start Date: December 2011
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Pharmacokinetic study
This will be a single dose study where participants will receive 20mg/kg or the participant's usual dose as a liquid containing hydroxyurea 100mg/mL. For a subset of participants (n= at least 6), a multiple-dose, steady state (i.e. at least 4 consecutive days of dosing) study will be performed.
Drug: Hydroxyurea
20mg/kg of Hydroxyurea or the patient's standard daily dose
Other Names:
  • Droxia Capsules
  • Hydrea
Active Comparator: Arm 2: Relative bioavailability study
This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
Drug: Hydroxyurea
20mg/kg of Hydroxyurea or the patient's standard daily dose
Other Names:
  • Droxia Capsules
  • Hydrea

  Eligibility

Ages Eligible for Study:   2 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

For Both Arms:

Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell

  • The study participant will be a pediatric (male or female) participant with sickle cell anemia with laboratory (i.e. electrophoretic, chromatographic or DNA) confirmation of the diagnosis of Hemoglobin SS or Sβ0thalassemia.
  • Weight ≥ 10 kg.
  • Participants may or may not be currently receiving hydroxyurea. If participants are taking hydroxyurea, the last dose must be no less than 24 hours prior to the start of the study.
  • Participant is in the "well" state (i.e. at least 2 weeks since the last vaso-occlusive crisis, acute chest syndrome episode, or splenic sequestration episode).
  • Clinical evidence of normal gastrointestinal function and structure.
  • No clinical evidence of hepatic compromise including transaminases no more than 3 times the upper limit of normal.
  • A glomerular filtration rate (GFR--estimated from serum creatinine using age-appropriate, validated equations such as the Schwartz equation) > 70 ml/min/1.73m2 and no known renal impairment (creatinine no more than 1.5 times the upper limit of normal for age in the screening laboratory).
  • Body mass index (BMI) ≥5th and ≤ 95th percentile as per CDC growth charts.
  • The parent or guardian is willing and able to provide a signed and dated written informed consent form prior to any study related procedures. When appropriate, the participant has signed an assent to participate according to local IRB guidelines.
  • The participants and/or participant's parents are able to understand and comply with protocol requirements, instructions, and protocol-stated restrictions such that the participant is likely to complete the study as planned.
  • Based on the opinion of the physicians providing patient care and those conducting the study, there are no apparent contraindications for inclusion as a participant in a pharmacokinetic study.
  • For the Pharmacokinetic Study (Arm 1):
  • Participant is ≥ 2 years and ≤ 5 years of age.
  • The participant is able to consume a minimum of 30 ml of water following ingestion of the study article.
  • For the Relative Bioavailability Study:
  • Participant is > 5 years and < 17 years of age.
  • All females of child-bearing potential must be found to have a negative serum pregnancy test prior to initial dosing and be willing to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy testing through the remainder of the study (30 days after last administration of investigational agents).
  • The participant is able to ingest both capsule and liquid study articles and consume a minimum of 30 ml of water following ingestion of medication.

EXCLUSION CRITERIA

  • A participant will not be eligible for inclusion in this study if any of the following criteria apply:
  • Chronic transfusion therapy, or transfused within 3 months of study participation.
  • Known renal impairment (creatinine greater than 1.5 times the upper limit of normal for age in the screening laboratory).
  • Known hepatic impairment or elevated transaminases (greater than 3 times normal).
  • Known presence of malignancy.
  • The participant is unwilling and/or unable to abstain from use of tobacco- or nicotine-containing products for 24 hours prior to screening and for 24 hours prior to dosing until collection of the final PK sample during each treatment period.
  • Diagnoses other than sickle cell anemia or sickle beta-zero thalassemia (i.e., other sickle cell variants or sickle hereditary persistence of fetal hemoglobin).
  • Blood count parameters as follows: Hemoglobin less than 6.0 gm/dL, absolute reticulocyte count less than 80,000 mm-3, neutrophil count less than 1200 mm-3, platelet count less than 150,000 mm-3.
  • The participant has used opiates, H2 blockers, proton pump inhibitors, antacids, other GI motility agents or any other medication that, in the opinion of the investigator and/or sponsor, will interfere with the study procedures or affect the interpretation of the results of the study for 3 days prior to the first dose of study.
  • Use of over the counter non-steroidal anti-inflammatory agent or narcotic analgesic within 3 days.
  • Participant has received an investigational drug within the past 30 days.
  • Use of any illicit or illegal substances.
  • The parent or guardian is unwilling or unable to provide a signed and dated written informed consent form prior to any study related procedures, or, when appropriate, the participant has refused to sign an assent to participate according to local IRB guidelines.
  • Any other condition or chronic illness, which in the opinion of the Principal Investigator makes participation unadvised or unsafe.
  • The caregiver is unwilling or unable to provide a completed study diary for a participant in the steady-state subset.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01506544

Contacts
Contact: Jaylene Weigel, RN, MSN, CCRC 816-701-1338 jweigel@cmh.edu
Contact: Amy Fox, MA 816-701-1357 arfox@cmh.edu

Locations
United States, Alabama
Children's Hospital of Alabama Recruiting
Birmingham, Alabama, United States, 35233
Contact: Melissa Bagwell    205-558-2983    melissa.bagwell@childrensal.org   
Principal Investigator: Thomas Howard, MD         
United States, Illinois
Children's Memorial Hospital (Northwestern University) Recruiting
Chicago, Illinois, United States, 60614-3363
Contact: Stephanie Pelligra    773-880-3871    spelligra@childrensmemorial.org   
Principal Investigator: Robert Liem, MD         
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Michael Morgan    212-304-5688    mpm2146@columbia.edu   
Principal Investigator: Nancy Green, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Hai Huang    919-613-4676    h.hai@duke.edu   
Principal Investigator: Courtney Thornburg, MD         
United States, Texas
UT Southwestern University Hospital Recruiting
Dallas, Texas, United States, 75390-9063
Contact: Leah Adix    214-456-2888    leah.adix@childrens.com   
Principal Investigator: Zora Rogers, MD         
United States, Wisconsin
Children's Hospital of Wisconsin Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Sylvia Torres    414-456-7563    storres@mcw.edu   
Principal Investigator: Amanda Brandow, MD         
Sponsors and Collaborators
Children's Mercy Hospital Kansas City
Investigators
Principal Investigator: Kathleen Neville, MD, MS Children's Mercy Hosptials and Clinics
  More Information

No publications provided

Responsible Party: Kathleen A Neville, Associate Professor of Pediatrics, Children's Mercy Hospital Kansas City
ClinicalTrials.gov Identifier: NCT01506544     History of Changes
Other Study ID Numbers: Hydroxyurea Pharmacokenetic, HHSN275201000003I
Study First Received: September 30, 2011
Last Updated: May 31, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Mercy Hospital Kansas City:
HU
Hydroxyurea
Sickle cell
Pediatric

Additional relevant MeSH terms:
Anemia
Anemia, Sickle Cell
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Hydroxyurea
Antineoplastic Agents
Antisickling Agents
Enzyme Inhibitors
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014